Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17250
Corporate User License Price USD 750
Corporate User License Price INR 51750
Site License Price USD 500
Site License Price INR 34500
Request a Quote

Report Title

Elsalys Biotech SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Elsalys Biotech SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Elsalys Biotech SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Elsalys Biotech SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

Elsalys Biotech SA (Elsalys Biotech) is a pharmaceutical company that develops new generation antibodies to modulate the immune system of patients with cancer or rare haematological diseases. The company's pipeline programs include anti-CD160, for macular degeneration or certain retinopathies; anti-CD160, for solid tumors and blood cancer; anti-Tyro3, for solid tumors; and anti-S100b, for idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. It also develops Leukotac, an immunotherapy antibody developed for the treatment of orphan disease with very poor prognosis: steroid-resistant acute graft versus host disease. Elsalys Biotech's specialization spans from target sourcing to the pre-industrial production of drug candidates. The company works in collaboration with academic and other industry partners to conduct programs, clinical evaluation of antibody candidates and to develop immune-based therapies. Elsalys Biotech is headquartered in Lyon, France.

Elsalys Biotech SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Elsalys Biotech SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 10

ElsaLys Biotech Acquires Rights of Anti-CD160 Antibody from MabLife 11

Venture Financing 12

ElsaLys Biotech Raises Additional USD3 Million in Financing Round 12

ElsaLys Biotech Raises USD 2.7 Million In First Round Of Financing 13

Licensing Agreements 15

Laboratoires Thea Enters into Licensing Option Agreement with Elsalys Biotech 15

Elsalys Biotech Enters into Licensing Agreement with Transgene 16

ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 17

Equity Offering 18

Elsalys Biotech Files Registration Statement to Raise Funds in IPO 18

Acquisition 19

Transgene Acquires 37% Stake in ElsaLys Biotech 19

Elsalys Biotech SA-Key Competitors 20

Elsalys Biotech SA-Key Employees 21

Elsalys Biotech SA-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Corporate Communications 23

Jan 30, 2017: Elsalys Biotech expands its team to strengthen its strategy and the development of its programs 23

Product News 25

04/05/2018: Elsalys Biotech: LEUKOTAC takes next step in paediatric acute steroid-resistant GvHD 25

03/15/2018: EUKOTAC at the 44th Congress of the European Society for Blood and Marrow Transplantation (EBMT) 26

Clinical Trials 27

Jul 18, 2017: ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU 27

Appendix 28

Methodology 28

About GlobalData 28

Contact Us 28

Disclaimer 28

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Key Facts 2

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Elsalys Biotech SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Elsalys Biotech SA, Deals By Therapy Area, 2012 to YTD 2018 8

Elsalys Biotech SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 10

ElsaLys Biotech Acquires Rights of Anti-CD160 Antibody from MabLife 11

ElsaLys Biotech Raises Additional USD3 Million in Financing Round 12

ElsaLys Biotech Raises USD 2.7 Million In First Round Of Financing 13

Laboratoires Thea Enters into Licensing Option Agreement with Elsalys Biotech 15

Elsalys Biotech Enters into Licensing Agreement with Transgene 16

ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 17

Elsalys Biotech Files Registration Statement to Raise Funds in IPO 18

Transgene Acquires 37% Stake in ElsaLys Biotech 19

Elsalys Biotech SA, Key Competitors 20

Elsalys Biotech SA, Key Employees 21

Elsalys Biotech SA, Other Locations 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Elsalys Biotech SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person